AnaptysBio Inc. (ANAB) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

AnaptysBio Inc. (ANAB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

14.94

0.32 (2.19%)

At close: Jan 14, 2025, 3:59 PM

14.91

-0.20%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	14
Market Cap	454.60M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-6.05
PE Ratio (ttm)	-2.47
Forward PE	n/a
Analyst	Buy

Ask	22
Volume	641,650
Avg. Volume (20D)	629,673
Open	14.77
Previous Close	14.62
Day's Range	14.37 - 15.63
52-Week Range	12.51 - 41.31
Beta	undefined

About ANAB

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 26, 2017

Employees 117

Stock Exchange NASDAQ

Ticker Symbol ANAB

Website https://www.anaptysbio.com

Analyst Forecast

According to 11 analyst ratings, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 154.35% from the latest price.

Buy 63.64%

Hold 36.36%

Sell 0.00%

Stock Forecasts

Next Earnings Release

AnaptysBio Inc. is scheduled to release its earnings on Mar 10, 2025, during market hours.
Analysts project revenue of $10.09M, reflecting a 12.05% YoY growth and earnings per share of -1.74, making a 9.43% increase YoY.

Why Price Moved

1 month ago · Source

-32.83%

AnaptysBio shares are trading lower after the comp... Unlock content with Pro Subscription

1 month ago · Source

-2.32%

AnaptysBio shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

News

2 days ago · zacks.com

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 month ago · zacks.com

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

1 month ago · benzinga.com

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monot...

1 month ago · reuters.com

AnaptysBio to abandon eczema drug development after mid-stage trial failure

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 4...

1 month ago · reuters.com

AnaptysBio abandons eczema drug development after mid-stage trial failure

AnaptysBio said on Wednesday that it would discontinue the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.

1 month ago · zacks.com

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Here is how AnaptysBio, Inc. (ANAB) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

2 months ago · zacks.com

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

AnaptysBio (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts...

2 months ago · zacks.com

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $1.41 per share a year ago.